Birgitte Offersen

Professor, MD, chair of DBCG, breast cancer researcher, Aarhus University Hospital, Experimental Clinical Oncology, Danish Centre for Particle Therapy.

[Birgitte Offersen @BOffersen]

Together with my colleague we have recorded a session on target volume delineation in an early breast cancer patient. It’s a one hour session with tips and tricks, link below #estro #breastcancer 🤓👇

https://t.co/nNo0pF4WBT

[Birgitte Offersen @BOffersen]

Excellent. High-risk pts should be offered RNI incl IMN now. The analysis also shows gain from RNI in node-negative pts and that needs to be discussed. Looking forward🧐

[Matthias Guckenberger @Mat_Guc]

Virtual Grand Rounds in Radiation Oncology

January 10th 17:00 - 17:30 CET

Prof. Carolyn Taylor:
Effect of regional lymph node radiotherapy. An EBCTCG meta-analysis of 14,324 women in 16 trials

Link to Zoom Meeting 👇
https://t.co/VMPm8mpHbj

[Ane Appelt @cancerphysicist]

I am SO excited about this!!! 🤩
We've put together a brilliant (in my humble opinion😉) line-up of speakers to discuss the challenges facing clinical re-irradiation. Please join us, it's going to be so much fun!
#ReIrradiation #medphys #radonc

[Birgitte Offersen @BOffersen]

@brunomeduri Interesting. Where can I find the quality assurance of the RT? Was level 1 fully irradiated in pts without surgery? Are we facing another Z0011 discussion about level 1 RT 🧐

[Birgitte Offersen @BOffersen]

@jfcdrr Probably 5 yr

[Birgitte Offersen @BOffersen]

Agree. RT is postponed for those who need it following a second breast conservation. Most likely a LR in these selected pts does not lead to distant failure. We have now randomised 600 pts in the DBCG Natural trial to +- partial breast RT. Heading for 926 pts🧐

[Hope Rugo @hoperugo]

Really important study!! We need to avoid over treatment when it doesn't help! @OncoAlert

[Birgitte Offersen @BOffersen]

Helt enig👍. Lyder for godt til at være sandt, og jeg kan ikke finde Djævelen i detaljen…. Det ser ud til, at de mener det🤩🤓. Super måde at rekruttere, tillykke til dem, som får stillingerne🥂🧐

[𝐌𝐀𝐑𝐈𝐀𝐍𝐍𝐄 𝐕𝐎𝐆𝐒𝐄𝐍 @marianne_vogsen]

Det her er altså en RIGTIG god ide @HerlevGentofte‼️ mindst 20% finansieret forskningstid, som led i hoveduddannelsesstilling 💪🏼en god mulighed for karriereudvikling for @YngreLaeger 👏🏼 #forskpol #uddpol #sundpol ➡️ https://t.co/Oq1ztAtzbh

[Birgitte Offersen @BOffersen]

@christian_roenn @CaiGrau Indeed deserved🍾🇩🇰🤩

[Birgitte Offersen @BOffersen]

@j_grau_eriksen @EHNSnews Tillykke Jesper⭐️👍

[Birgitte Offersen @BOffersen]

The figure on the cover is from the editorial—>use the ESTRO guidelines and report your results accordingly🧐. Lift the threshold for RT details when reporting RT from clinical studies: e.g. RT technique, target def., dose/fr, doses to OAR, etc

[Radiotherapy & Oncology @RO_GreenJournal]

Vol 179 - just published

[Birgitte Offersen @BOffersen]

@rufusgifford Lovely true love ❤️. Fingers crossed for fast recovery🤞

[Birgitte Offersen @BOffersen]

Link to article: https://t.co/Y7VFNH6Of1

[Birgitte Offersen @BOffersen]

Radiation associated induration is closely related to irradiated breast volume in the DBCG PBI trial. Validation in the DBCG Hypo trial showed surprising and interesting findings. More info at ESTRO2023 @ESTRO_RT @RadiotherapyOn1

[Birgitte Offersen @BOffersen]

@merino_tomas Proton is a meeting the day before BIGART. The BIGART is mostly biology, imaging and translational research in photons

[Birgitte Offersen @BOffersen]

BIGART is truly a great conference🧐. I am looking forward to the meeting⭐️

[Birgitte Offersen @BOffersen]

@DCCC_RT @acrobatic_dk Super godt at vi sammen forhåbentlig kan give længere progressionsfri overlevelse til vores patienter samtidig med relativ skånsom behandling 👍

[Birgitte Offersen @BOffersen]

Congratulations to Michael. What an honour to have several doctor titles 🥂🤓⭐️🇩🇰

[Jens Overgaard @profOvergaard]

A good day for radiation oncology and Aarhus University
Professor Michael Baumann DKFZ recieve a honorary doctorate: https://t.co/WldcLq0pPj honoris causa
Congratulations

[Birgitte Offersen @BOffersen]

@jeris_123 Since 2018 all Danish PBI candidates age minimum 60yr are offered randomisation in the DBCG RT Natural trial, which is 40Gy/15fr PBI versus no RT. Thus, we use 15 fr as SOC. You are invited to participate👍

[Birgitte Offersen @BOffersen]

The first results from the DBCG PBI trial support standard use of external beam PBI 40Gy/15fr for selected breast cancer pts. Less morbidity and very few cancer events (not related to PBI). PBI has been DBCG standard since 2016 for low risk BC pts.
Graphs & link below 👇

[Birgitte Offersen @BOffersen]

@BLawenda No difference in cardiac morbidity…..

[Birgitte Offersen @BOffersen]

Link to paper: https://t.co/jYQWls5WFn

[Birgitte Offersen @BOffersen]

The pts were minimum 60 yr at randomisation (median 66 yr), and the causes of death were mostly related to non-breast disease.